If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.


SCHEDULE 13D


 
Jeito II S.L.P.
 
Signature:/s/ Rafaele Tordjman
Name/Title:Rafaele Tordjman, CEO of Jeito Capital SAS acting as management company of Jeito II S.L.P.
Date:05/15/2026
 
Jeito Capital SAS
 
Signature:/s/ Rafaele Tordjman
Name/Title:Rafaele Tordjman, CEO
Date:05/15/2026
 
Rafaele Tordjman
 
Signature:/s/ Rafaele Tordjman
Name/Title:Rafaele Tordjman
Date:05/15/2026
 
Sabine Dandiguian
 
Signature:/s/ Sabine Dandiguian
Name/Title:Sabine Dandiguian
Date:05/15/2026

 

Exhibit 99.1

 

 

Joint Filing Agreement

 

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing of a Statement on Schedule 13D (including amendments thereto) with respect to the common stock of Odyssey Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit thereto. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement this 15th day of May, 2026.

 

  JEITO II S.L.P.
   
  By: /s/ Rafaele Tordjman
    Rafaele Tordjman, CEO of Jeito Capital SAS acting as management company of Jeito II S.L.P.

 

 

  JEITO Capital SAS
   
  By: /s/ Rafaele Tordjman
    Rafaele Tordjman, CEO

 

 

  Rafaele Tordjman
   
  By: /s/ Rafaele Tordjman

 

 

  Sabine Dandiguian
   
  By: /s/ Sabine Dandiguian